Clinical characteristics of tobacco smoke-induced versus biomass fuel-induced chronic obstructive pulmonary disease

被引:17
|
作者
Cheng, Lin-ling [1 ]
Liu, Ya-ya [2 ]
Su, Zhu-quan [1 ]
Liu, Jun [1 ]
Chen, Rong-chang [1 ]
Ran, Pi-xin [1 ]
机构
[1] Guangzhou Med Univ, Guangzhou Inst Resp Dis, Key State Lab Resp Dis, Guangzhou, Guangdong 510120, Peoples R China
[2] Guangzhou Profess Coll Foods & Drugs, Guangzhou, Guangdong 510120, Peoples R China
关键词
chronic obstructive pulmonary disease; smoking; biomass fuels; clinical characteristics;
D O I
10.1515/jtim-2015-0012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate differences in clinical features between tobacco smoke-induced and biomass fuel-induced chronic obstructive pulmonary disease (COPD). Methods: We retrospectively analyzed 206 patients with COPD caused by exposure to tobacco smoke and 81 cases of COPD caused by exposure to biomass fuels who received treatment in our hospital between 2011 March and 2014 March. Difference in general health status, clinical symptoms, the dyspnea score, and comorbidities between the two groups were compared. In addition, pulmonary function, grading, and acute exacerbations were also compared. Results: (1) Difference in general health status: Male and female patients with COPD caused by exposure to tobacco smoke were 83.5 and 16.5%, respectively. Male and female patients with COPD caused by exposure to smoke from biomass fuels were 14.8 and 85.2% (chi(2) = 27.2, P < 0.05), respectively. Tobacco smoke-induced COPD was more prevalent in men, and COPD caused by exposure to smoke from biomass fuels was more prevalent in women. After gender adjustment, body mass index (BMI) was lower in women with COPD caused by exposure to smoke from biomass fuels than those by tobacco smoke. There was no statistically significant difference in other indicators, such as age. (2): Difference in clinical symptoms: No statistically significant difference in the modified British Medical Research Counsel (mMRC) Questionnaire, a measure of breathlessness, was observed between the two groups. Dyspnea was more common in COPD patients that was caused by exposure to biomass fuels (38.3%) than by tobacco smoke (11.1%) (chi(2) = 17.9, P < 0.05). The comorbidities of allergic diseases (such as allergic rhinitis, bronchial asthma) were more prevalent in COPD patients that was caused by exposure to smoke from biomass fuels (43.2%) than by tobacco smoke (18%) (chi(2) = 16.1, P < 0.05). However, COPD comorbid with lung cancer was more prevalent in those cases that were caused by exposure to tobacco smoke (7.77%) than in cases caused by exposure to smoke from biomass fuels (3.7%) (chi(2) = 9.7, P < 0.05). (3) Differences in grading of pulmonary function: After gender adjustment, patients with COPD caused by exposure to biomass fuels were mostly in grade B or D. (4) Exacerbations: No significant difference in exacerbations per year was noted between the two groups. Conclusions: Marked differences exist between patients with COPD caused by exposure to tobacco smoke and smoke from biomass fuels. Patients with COPD caused by exposure to biofuels are mostly females with lower BMI and often with many clinical symptoms and complications, such as allergic rhinitis and bronchial asthma. Such patients are often in stage B or D. Tobacco smoke-induced COPD is more prevalent in male patients, often with complications in the form of lung cancer.
引用
收藏
页码:126 / 129
页数:4
相关论文
共 50 条
  • [21] Pulmonary hypertension frequency in patients with chronic obstructive pulmonary disease exposed to biomass or tobacco smoke
    Sertogullarindan, Bunyamin
    Gumrukcuoglu, Hasan Ali
    Sezgi, Cengizhan
    Akil, Mehmet Ata
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [22] A novel non-human primate model of cigarerte smoke-induced chronic obstructive pulmonary disease
    Polverino, Francesca
    Doyle-Eisele, Melanie
    McDonald, Jacob
    Wilder, Julie
    Kelly, Emer
    Mauderly, Joe
    Pinto-Plata, Victor
    Divo, Miguel
    Celli, Bartolome
    Tesfaigzi, Yohannes
    Owen, Caroline Ann
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [23] RANKL Mediates Muscle Atrophy and Dysfunction in a Cigarette Smoke-induced Model of Chronic Obstructive Pulmonary Disease
    Xiong, Jing
    Le, Yanqing
    Rao, Yafei
    Zhou, Lu
    Hu, Yuhan
    Guo, Suliang
    Sun, Yongchang
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2021, 64 (05) : 617 - 628
  • [24] Role of Cigarette Smoke-Induced Aggresome Formation in Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis
    Ian Tran
    Ji, Changhoon
    Ni, Inzer
    Min, Taehong
    Tang, Danni
    Vij, Neeraj
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2015, 53 (02) : 159 - 173
  • [25] Progesterone (P4) ameliorates cigarette smoke-induced chronic obstructive pulmonary disease (COPD)
    Xie, Bin
    Chen, Qiong
    Dai, Ziyu
    Jiang, Chen
    Chen, Xi
    MOLECULAR MEDICINE, 2024, 30 (01)
  • [26] Cigarette Smoke-induced Oxidative Stress A Role in Chronic Obstructive Pulmonary Disease Skeletal Muscle Dysfunction
    Barreiro, Esther
    Peinado, Victor I.
    Galdiz, Juan B.
    Ferrer, Elisabet
    Mann-Corral, Judith
    Sanchez, Francisco
    Gea, Joaquim
    Albert Barbera, Joan
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (04) : 477 - 488
  • [27] Taxifolin ameliorates cigarette smoke-induced chronic obstructive pulmonary disease via inhibiting inflammation and apoptosis
    Liu, Xiangming
    Ma, Yiming
    Luo, Lijuan
    Zeng, Zihang
    Zong, Dandan
    Chen, Yan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 115
  • [28] A Novel Non-Human Primate Model Of Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease
    Polverino, F.
    Doyle-Eisele, M.
    McDonald, J.
    Wilder, J. A.
    Kelly, E.
    Mauderly, J.
    Pinto-Plata, V. M.
    Divo, M.
    Celli, B. R.
    Tesfaigzi, Y.
    Owen, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [29] Time-resolved proteomic profiling of cigarette smoke-induced experimental chronic obstructive pulmonary disease
    Skerrett-Byrne, David A.
    Bromfield, Elizabeth G.
    Murray, Heather C.
    Jamaluddin, M. Fairuz B.
    Jarnicki, Andrew G.
    Fricker, Michael
    Essilfie, Ama T.
    Jones, Bernadette
    Haw, Tatt J.
    Hampsey, Daniel
    Anderson, Amanda L.
    Nixon, Brett
    Scott, Rodney J.
    Wark, Peter A. B.
    Dun, Matthew D.
    Hansbro, Philip M.
    RESPIROLOGY, 2021, 26 (10) : 960 - 973
  • [30] Enhancing tristetraprolin activity reduces the severity of cigarette smoke-induced experimental chronic obstructive pulmonary disease
    Nair, Prema M.
    Starkey, Malcolm R.
    Haw, Tatt Jhong
    Liu, Gang
    Collison, Adam M.
    Mattes, Joerg
    Wark, Peter A.
    Morris, Jonathan C.
    Verrills, Nikki M.
    Clark, Andrew R.
    Ammit, Alaina J.
    Hansbro, Philip M.
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2019, 8 (10)